12:00 AM
 | 
Nov 09, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Emzetimibe/atorvastatin regulatory update

FDA refused to file an NDA from Merck for ezetimibe/atorvastatin to treat dyslipidemia. The company said FDA indicated that additional...

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >